[go: up one dir, main page]

EP2016944A3 - Inhibiteur de l'angiogénèse comprenant un dérivé de la rifampicine - Google Patents

Inhibiteur de l'angiogénèse comprenant un dérivé de la rifampicine Download PDF

Info

Publication number
EP2016944A3
EP2016944A3 EP08168507A EP08168507A EP2016944A3 EP 2016944 A3 EP2016944 A3 EP 2016944A3 EP 08168507 A EP08168507 A EP 08168507A EP 08168507 A EP08168507 A EP 08168507A EP 2016944 A3 EP2016944 A3 EP 2016944A3
Authority
EP
European Patent Office
Prior art keywords
angiogenesis
present
rifampicin
derivative
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08168507A
Other languages
German (de)
English (en)
Other versions
EP2016944A2 (fr
Inventor
Masayoshi Shichiri
Yujiro Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHICHIRI Masayoshi
TANAKA, YUJIRO
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2016944A2 publication Critical patent/EP2016944A2/fr
Publication of EP2016944A3 publication Critical patent/EP2016944A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
EP08168507A 2002-06-21 2003-06-19 Inhibiteur de l'angiogénèse comprenant un dérivé de la rifampicine Withdrawn EP2016944A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002181281 2002-06-21
JP2003118960A JP4393098B2 (ja) 2002-06-21 2003-04-23 アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
EP03733506A EP1516620B1 (fr) 2002-06-21 2003-06-19 Rifampicin pour le traitment de l'angiogenese

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP03733506A Division EP1516620B1 (fr) 2002-06-21 2003-06-19 Rifampicin pour le traitment de l'angiogenese

Publications (2)

Publication Number Publication Date
EP2016944A2 EP2016944A2 (fr) 2009-01-21
EP2016944A3 true EP2016944A3 (fr) 2009-12-02

Family

ID=30002254

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08168507A Withdrawn EP2016944A3 (fr) 2002-06-21 2003-06-19 Inhibiteur de l'angiogénèse comprenant un dérivé de la rifampicine
EP03733506A Expired - Lifetime EP1516620B1 (fr) 2002-06-21 2003-06-19 Rifampicin pour le traitment de l'angiogenese

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP03733506A Expired - Lifetime EP1516620B1 (fr) 2002-06-21 2003-06-19 Rifampicin pour le traitment de l'angiogenese

Country Status (6)

Country Link
US (2) US20060035878A1 (fr)
EP (2) EP2016944A3 (fr)
JP (1) JP4393098B2 (fr)
KR (2) KR20070008719A (fr)
DE (1) DE60325855D1 (fr)
WO (1) WO2004000307A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008001720A (ja) * 2002-06-21 2008-01-10 Japan Science & Technology Agency アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
KR20080081351A (ko) * 2006-01-04 2008-09-09 도꾜 메디칼 앤드 덴탈 유니버시티 간장 질환 치료제 및 간기능 개선제
WO2007148714A1 (fr) * 2006-06-21 2007-12-27 Kaneka Corporation Implant utilisant un dérivé de rifamycine
WO2007148713A1 (fr) * 2006-06-21 2007-12-27 Kaneka Corporation Médicament pour traiter une maladie vasculaire ou médicament pour contrôler la prolifération cellulaire comprenant un dérivé de rifamycine en tant que principe actif
JP2010111582A (ja) * 2007-02-15 2010-05-20 Tokyo Medical & Dental Univ リファンピシンを成分とする肝臓癌治療剤
EP2333546A4 (fr) * 2008-08-28 2011-12-21 Nat Univ Corp Tokyo Med & Dent Procédé de criblage d'un agent antiangiogénique et procédé de criblage du gène associé au signal antiangiogénique
US20170202850A1 (en) 2014-07-21 2017-07-20 Hiroaki Serizawa Ophthalmic compositions of rifamycins and uses thereof
JP7187310B2 (ja) * 2015-10-08 2022-12-12 エーエムディー セラピューティックス エルエルシー Ｖｅｇｆ阻害剤の局所投与による皮膚障害の処置
KR102613900B1 (ko) * 2015-11-13 2023-12-15 서울대학교 산학협력단 HO-1 유전자 및 TNFR1-Fc 유전자를 동시에 발현하며 GGTA1 유전자가 넉아웃된 형질전환 돼지 및 이의 용도
KR101916801B1 (ko) * 2016-08-12 2018-11-08 경북대학교 산학협력단 3차원 생체 모사 시스템을 이용한 맥락막 혈관신생을 수반하는 질환의 치료제 스크리닝 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058126A1 (fr) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Utilisation de neomycine pour le traitement de maladies associees a l'angiogenese

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5339400A (fr) 1976-09-22 1978-04-11 Iwanouitsuchi Ponomar Arekusei
JPS5740155A (en) 1980-08-19 1982-03-05 Ishikawajima Harima Heavy Ind Co Ltd Overload safety device
JPS6241673A (ja) 1985-08-14 1987-02-23 ハワ−ド　エ−　サツセ ゴルフ・クラブ
JPS6241671A (ja) 1985-08-15 1987-02-23 コスモ石油株式会社 ガス遮断装置
JPS6241672A (ja) 1985-08-15 1987-02-23 日本ドライケミカル株式会社 窓硝子破壊器
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance
JPH0544467A (ja) 1991-08-19 1993-02-23 Nippondenso Co Ltd エンジン用ウオータポンプ
US6406880B1 (en) * 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
JP2003517816A (ja) * 1999-08-11 2003-06-03 イオス バイオテクノロジー， インコーポレイテッド 新脈管形成の診断の新規方法、新脈管形成調節因子についてのスクリーニングの組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058126A1 (fr) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Utilisation de neomycine pour le traitement de maladies associees a l'angiogenese

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEMKOW URSZULA ET AL: "The influence of rifampicin on selected parameters of immunological response", PNEUMOLOGIA I ALERGOLOGIA POLSKA, POLSKIE TOWARZYSTWO FTIZJOPNEUMONOLOGICZNE, WARZAW, PL, vol. 66, no. 1-2, 1 January 1998 (1998-01-01), pages 45 - 53, XP002971161, ISSN: 0867-7077 *
MALKOWSKA-ZWIERZ ET ALL.: "Anti-angiogenic effects of some anti-microbial drugs", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 7, 1995, pages 968, XP008050065 *

Also Published As

Publication number Publication date
JP2004075665A (ja) 2004-03-11
KR20050008773A (ko) 2005-01-21
KR20070008719A (ko) 2007-01-17
DE60325855D1 (de) 2009-03-05
EP2016944A2 (fr) 2009-01-21
EP1516620A4 (fr) 2005-09-07
US20060035878A1 (en) 2006-02-16
US20100004327A1 (en) 2010-01-07
US9333194B2 (en) 2016-05-10
JP4393098B2 (ja) 2010-01-06
WO2004000307A1 (fr) 2003-12-31
KR100678494B1 (ko) 2007-02-06
EP1516620B1 (fr) 2009-01-14
EP1516620A1 (fr) 2005-03-23

Similar Documents

Publication Publication Date Title
HUP0300544A2 (hu) Integrin expresszálás inhibitorokat tartalmazó gyógyszerkészítmények
IS7840A (is) 3-(3,5-díoxó-4,5-díhýdró-3H-(1,2,4)tríasín-2-ýl)-bensamíð afleiður sem P2X7-hindrar til notkunar í meðferð á bólguvaldandi sjúkdómum
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
WO2003053368A3 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
WO2006065277A3 (fr) Inhibiteurs d'aspartyle protease heterocycliques
NO20061454L (no) Compounds having CRTH2 antagonist activity
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
WO2002051837A3 (fr) Composes heterocyclylindazole et azaindazole utilises en tant que ligands 5-hydroxytryptamine-6
WO2004094388A3 (fr) Methodes de traitement d'une maladie inflammatoire ou d'inhibition de la proteine jnk
EP2329842A3 (fr) Inhibiteurs d'interleukine 1 dans le traitement de maladies
WO2005000298A3 (fr) Inhibiteurs de p-38
WO2006031806A3 (fr) 2-thiopyrimidinones utilises en tant qu'agents therapeutiques
WO2007109251A3 (fr) Inhibiteurs du facteur de nécrose tumorale alpha et leurs utilisations pour le traitement de maladies humaines
WO2003091259A8 (fr) Inhibiteurs de la triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase
WO2003065987A3 (fr) Inhibiteurs de granzyme b
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
AU4888401A (en) Sulfonamide derivative as a matrix metalloproteinase inhibitor
EP2016944A3 (fr) Inhibiteur de l'angiogénèse comprenant un dérivé de la rifampicine
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081106

AC Divisional application: reference to earlier application

Ref document number: 1516620

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): DE FR GB IT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TANAKA, YUJIRO

Owner name: SHICHIRI, MASAYOSHI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TANAKA, YUJIRO

Inventor name: SHICHIRI, MASAYOSHI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125864

Country of ref document: HK

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): DE FR GB IT

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20091028BHEP

Ipc: A61K 31/496 20060101ALI20091028BHEP

Ipc: A61P 3/10 20060101ALI20091028BHEP

Ipc: A61P 9/00 20060101ALI20091028BHEP

Ipc: A61P 27/02 20060101ALI20091028BHEP

Ipc: G01N 33/50 20060101ALI20091028BHEP

Ipc: A61P 43/00 20060101ALI20091028BHEP

Ipc: A61P 29/00 20060101ALI20091028BHEP

Ipc: A61K 31/395 20060101AFI20091028BHEP

Ipc: C07D 498/18 20060101ALI20091028BHEP

Ipc: G01N 33/15 20060101ALI20091028BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20091215

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1125864

Country of ref document: HK